The impact of Metastasis Suppressor-1, MTSS1, on oesophageal squamous cell carcinoma and its clinical significance

Journal of Translational Medicine

Wen G Jiang²  Lijian Zhang¹  Yue Yang¹  Zhiqian Zhang¹  Nan Wu¹  Jinfeng Chen¹  Lin Ye²  Fei Xie¹ 

[1] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Surgery, Peking University School of Oncology and Beijing Cancer Hospital, Beijing, 100142, China;Metastasis and Angiogenesis Research Group, Cardiff University School of Medicine, Cardiff, CF14 4XN, UK

关键词: metastasis;    oesophageal squamous cell carcinoma;    MIM;    MTSS1;    metastasis suppressor-1;   

Others  :  1207923
DOI  :  10.1186/1479-5876-9-95

 received in 2011-03-23, accepted in 2011-06-22,  发布年份 2011

【 摘 要 】

Background

Metastasis suppressor-1 (MTSS1) has been proposed to function as a cytoskeletal protein with a role in cancer metastasis. Recent studies have demonstrated the clinical significance of MTSS1 in certain type of cancers, yet the clinical relevance of MTSS1 in oesophageal squamous cell carcinoma (ESCC) has not been reported.

Methods

In this study, we assessed the expression levels of MTSS1 in tumours and its matched adjacent non-tumour tissues obtained from 105 ESCC patients. We also used ESCC cells with differing MTSS1 expression and assessed the influence of MTSS1 on ESCC cells.

Results

Down-regulation of MTSS1 expression was observed both in oesophageal tumour tissues and ESCC cancer cell lines. We also reported that MTSS1 expression was associated with tumour grade (p = 0.024), lymph node metastasis (p = 0.010) and overall survival (p = 0.035). Patients with high levels of MTSS1 transcripts had a favorable prognosis in comparison with those who had reduced or absent expression levels. Using over-expression and knockdown approach, we created sublines from ESCC cells and further demonstrated that MTSS1 expression in ESCC cells significantly influenced the aggressiveness of the oesophageal cancer cells, by reducing their cellular migration and in vitro invasiveness.

Conclusion

MTSS1 serves as a potential prognostic indicator in human ESCC and may be an important target for cancer therapy.

【 授权许可】

   
2011 Xie et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Steeg PS: Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 2003, 3:55-63.
• [2]Lee Y, Macoskay JA, Korenchukx S, Pientay KJ: MIM, a potential metastasis suppressor gene in bladder cancer. Neoplasia 2002, 4:291-294.
• [3]Ma S, Guan X, Lee TK, Chan KW: Clinicopathological significance of missing in metastasis B expression in hepatocellular carcinoma. Hum Pathol 2007, 38:1201-1206.
• [4]Lin J, Liu J, Wang Y, Zhu J, Zhou K, Smith N, Zhan X: Differential regulation of cortactin and N-WASP-mediated actin polymerization by missing in metastasis (MIM) protein. Oncogene 2005, 24:2059-2066.
• [5]Yamagishi A, Masuda M, Ohki T, Onishi H, Mochizuki N: A novel actin bundling/filopodium-forming domain conserved in insulin receptor tyrosine kinase substrate p53 and missing in metastasis protein. J Biol Chem 2004, 279:14929-14936.
• [6]Mattila PK, Salminen M, Yamashiro T, Lappalainen P: Mouse MIM, a tissue-specific regulator of cytoskeletal dynamics, interacts with ATP-actin monomers through its C-terminal WH2 domain. J Biol Chem 2003, 278:8452-8459.
• [7]Mattila P K, Pykäläinen A, Saarikangas J, Paavilainen VO, Vihinen H, Jokitalo E, Lappalainen P: Missing-in-metastasis and IRSp53 deform PI (4,5)P2-rich membranes by an inverse BAR domain-like mechanism. J Cell Biol 2007, 176:953-964.
• [8]Callahan CA, Ofstad T, Horng L, Wang JK, Zhen HH, Coulombe PA, Oro AE: MIM/BEG4, a Sonic hedgehog-responsive gene that potentiates Gli-dependent transcription. Genes Dev 2004, 18:2724-2729.
• [9]Nazarenko IA, Bhatnagar SK, Hohman RJ: A closed tube format for amplification and detection of DNA based on energy transfer. Nucleic Acids Res 1997, 25:2516-2521.
• [10]Jiang WG, Douglas-Jones A, Mansel RE: Level of expression of lipoxygenase-5, 12, and 15 and cyclooxygenase in human breast cancer. Prostaglaindins Leukotr Ess Fatty Acids 2003, 69:275-281.
• [11]Jiang WG, Grimshaw D, Lane J, Martin TA, Abounader R, Laterra J, Mansel RE: A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells. Clin Cancer Res 2001, 7:2555-62.
• [12]Parr C, Jiang WG: Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer. Eur J Cancer 2009, 45:1673-1683.
• [13]Jiang WG, Hiscox S, Hallett MB, Scott C, Horrobin DF, Puntis MC: Inhibition of hepatocyte growth factor-induced motility and in vitro invasion of human colon cancer cells by gamma-linolenic acid. Br J Cancer 1995, 71:744.
• [14]Jiang WG, Hiscox SE, Parr C, Martin TA, Matsumoto K, Nakamura T, et al.: Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. Clin Cancer Res 1999, 5:3695.
• [15]Nixdorf S, Grimm M, Loberg R, Marreiros A, Russell RJ, Pienta KJ, Jackson P: Expression and regulation of MIM (missing in metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines. Cancer Lett 2004, 215:209-220.
• [16]Utikal1 J, Gratchev A, Muller-Molinet I, Oerther S, Kzhyshkowska J, Arens N, Grobholz R, Kannookadan S, Goerdt S: The expression of metastasis suppressor MIM/MTSS1 is regulated by DNA methylation. Int J Cancer 2006, 119:2287-2293.
• [17]Loberg RD, Neeley CK, Adam-day LL, Fridman Y, St John LN, Nixdorf S, Jackson P, Kalikin LM, Pienta KJ: Differential expression analysis of MIM (MTSS1) splice variants and a functional role of MIM in prostate cancer cell biology. Int J Oncol 2005, 26:1699-1705.
• [18]Bompard G, Sharp SJ, Freiss G, Machesky LM: Involvement of Rac in actin cytoskeleton rearrangements induced by MIM-B. J Cell Sci 2005, 118:5393-5403.
• [19]Wang Y, Zhou K, Zeng X, Lin J, Zhan X: Tyrosine phosphorylation of missing in metastasis protein is implicated in platelet-derived growth factor-mediated cell shape changes. J Biol Chem 2007, 282:7624-7631.
• [20]Suetsugu S, Murayama K, Sakamoto A, Hanawa-Suetsugu K, Seto A, Oikawa T, Mishima C, Shirouzu M, Takenawa T, Yokoyama S: The RAC binding domain/IRSp53 -MIM homology domain of IRSp53 induces RAC-dependent membrane deformation. J Biol Chem 2006, 281:35347-35358.
• [21]Saarikangas J, Zhao H, Pykäläinen A, Laurinmäki P, Mattila PK, Kinnunen PK, Butcher SJ, Lappalainen P: Molecular mechanisms of membrane deformation by I-BAR domain proteins. Curr Biol 2009, 19:95-107.
• [22]Woodings JA, Sharp SJ, Machesky LM: MIM-B, a putative metastasis suppressor protein, binds to actin and to protein tyrosine phosphatase delta. Biochem J 2003, 371:463-71.
• [23]Xie F, Ye L, Ta M, Zhang L, Jiang WG: MTSS1: a multifunctional protein and its role in cancer invasion and metastasis. Front Biosci 2011, 3:621-31.
• [24]Saarikangas J, Mattila PK, Varjosalo M, Bovellan M, Hakanen J, Calzada-Wack J, et al.: Missing-in-metastasis MIM/MTSS1 promotes actin assembly at intercellular junctions and is required for intergrity of kidney epithelia. J Cell Sci 2011, 124:1245-1255.
• [25]Mustafa N, Martin TA, Jiang WG: Metastasis tumour suppresor-1, MTSS-1 and the aggressiveness of prostate cancer cells. Exp Therapeut Med 2011, 2:157-162.